Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 27
States / cities: Phoenix, Arizona • Bakersfield, California • San Diego, California + 23 more

Conditions: Psoriasis
Interventions: Anecdotal Evidence, Research Study Evidence, Anecdotal + Research Study Evidence, No Evidence; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic Plaque Psoriasis
Interventions: alefacept, polyvalent pneumococcal vaccine; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Birmingham, Alabama • San Diego, California • New York, New York + 1 more

Conditions: Arthritis, Psoriatic
Interventions: CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 27
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more

Conditions: Plaque Psoriasis
Interventions: Topicort® (desoximetasone) Topical Spray, 0.25%; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Psoriatic Arthritis
Interventions: Filgotinib, Adalimumab, Placebo to match filgotinib, Placebo to match adalimumab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 24
States / cities: Covina, California • Brandon, Florida • DeBary, Florida + 20 more

Conditions: Psoriatic Arthritis
Interventions: Human anti-TNF monoclonal antibody/adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Psoriasis, Aging, Epigenetic Disorder, Inflammation; Skin
Interventions: TILDRAKIZUMAB; Biological
Lead sponsor: Carlos Wambier; Other
Eligibility: 35 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Chronic Stable Plaque Psoriasis
Interventions: Clobex Spray, Vectical Ointment, Excimer Laser; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atopic Dermatitis, Psoriasis
Interventions: Vitamin D3, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: San Diego, California • Denver, Colorado • Portland, Oregon

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo, Risankizumab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 44
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 41 more

Conditions: Skin Diseases, Psoriasis
Interventions: LY3041658, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Glendale, California • Indianapolis, Indiana • Baltimore, Maryland + 2 more

Conditions: Psoriasis
Interventions: Anti IL-12 monoclonal antibody/ABT-874, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 16
States / cities: San Diego, California • Alpharetta, Georgia • Skokie, Illinois + 13 more

Conditions: Chronic Plaque-type Psoriasis
Interventions: AIN457, AIN457A, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 25 more

Conditions: Psoriasis
Interventions: PF-06700841, Vehicle (Placebo); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 38
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Anaheim, California + 31 more

Conditions: Chronic Plaque Psoriasis
Interventions: Calcitriol 3mcg/g; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 5
States / cities: Little Rock, Arkansas • San Diego, California • Eagan, Minnesota + 2 more

Conditions: Psoriasis Vulgaris
Interventions: deucravacitinib; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 38
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 34 more

Conditions: Psoriasis
Interventions: Ilumya Injectable Product; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Plaque-Type Psoriasis
Interventions: Olux-E Foam, Clobex lotion; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Psoriasis Vulgaris
Interventions: Active taVNS, Sham taVNS; Device
Lead sponsor: Burrell College of Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Las Cruces, New Mexico

Conditions: Psoriasis
Interventions: SAR441566, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 11
States / cities: Scottsdale, Arizona • Los Angeles, California • Boca Raton, Florida + 8 more

Conditions: Arthritis, Rheumatoid, Arthritis, Psoriatic, Psoriasis, Ankylosing Spondylitis, Autoimmune Diseases
Interventions: Root-cause autoimmune treatment program; Other
Lead sponsor: AndHealth; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Psoriasis Vulgaris
Interventions: LEO 90100 aerosol foam, LEO 90100 aerosol foam vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Fremont, California • Santa Monica, California • Denver, Colorado + 17 more

Search by objective public record fields.

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Assessing Patient Confidence in Biologic Medications

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

Effects of Tildrakizumab on Epigenetic Age

Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis

Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

A Study of LY3041658 in Participants With Skin Diseases

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis

Correction of Psoriatic T Cell Signatures by Deucravacitinib

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis

Augmenting Standard-of-care Treatment of Plaque Psoriasis by Neuromodulation

A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis

IMPACT - AndHealth Autoimmune Research Registry

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris